CJC-1295 with DAC record · updated 20h ago
CJC-1295 with DAC is a long-acting GHRH analog bound to serum albumin, studied as an investigational growth hormone secretagogue with a multi-day half-life and sustained IGF-1 elevation.
How it works: GHRH analog with drug-affinity complex (albumin-binding)
Development stage
where CJC-1295 with DAC sits between preclinical work and regulatory approval- 1CurrentPreclinicalAnimal / in-vitro work
- 2Not reachedPhase 1Safety in humans
- 3Not reachedPhase 2Efficacy signal
- 4Not reachedPhase 3Confirmatory trials
- 5Not reachedApprovedCleared by a regulator
Stage is inferred from the highest trial phase in the indexed corpus and 69 registered trials. It describes the research record, not a recommendation.
What people are saying
anecdotal · not evidenceUnverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching CJC-1295 with DAC will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.